Tinhofer et al. demonstrated that patients with squamous cell carcinoma of the head and neck (SCCHN) who showed high AREG expression were less likely to benefit from combination treatment with cetuximab and docetaxel [10]. The gene discussed is AREG; the disease is head and neck squamous cell carcinoma.